Accenture and NovoCure Shares Plunge Amid Tech and Healthcare Sector Volatility

Key Facts

1Accenture shares fell 16.32% to $130.55 following its earnings announcement despite reporting revenue growth.

2NovoCure stock dropped 20% after its brain tumor treatment failed to meet primary goals in a late-stage clinical trial.

3Inverse ETFs for SMCI and MU saw significant declines, indicating strong upward movement in the underlying semiconductor stocks.

Amid heightened market sensitivity to corporate earnings and future growth outlooks, technology and healthcare stocks faced intense selling pressure. Accenture shares tumbled 16.32% to $130.55 following its earnings announcement, despite the company reporting revenue growth. In the biotech sector, NovoCure stock plunged 20% after its brain tumor treatment failed to meet primary goals in late-stage clinical trials, while inverse ETFs for SMCI and MU saw significant declines.

Accenture's performance reflects a divergence from its tech consulting peers as markets closely monitor the ability to monetize AI investments into sustainable earnings. In contrast to the broader tech weakness, market data showed strength in underlying semiconductor stocks like Micron Technology, which triggered drops in inverse ETFs. Per market data, NovoCure's trial failure highlights the high-stakes nature of the biotech sector, where investors remain highly selective based on clinical outcomes.

Regarding current price levels, ACN closed at $156.01 and SMCI at $27.78 (close June 17, 2026), while MU is trading at $1140 (close June 18, 2026). Investors should watch upcoming catalysts, including the Michigan Consumer Sentiment index, to gauge the resilience of institutional and consumer spending and its subsequent impact on growth stocks.